UBS upgrades uniQure to Buy, target raised to $48
Alpha Vantage · GuruFocus · · AI-summarised by FinFlash
UBS upgraded uniQure to Buy and raised its price target to $48 from $27, citing renewed optimism about the gene therapy company's potential. The bullish call contrasts with GuruFocus data showing QURE significantly overvalued, with a GF Value of $8.03 and a GF Score of 49/100 on financial strength and profitability concerns.
Understand the context
Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.